Koers Rezolute, Inc. Other OTC
Aandelen
US76200L1017
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 23,49 mln. 21,84 mln. | Marktkapitalisatie | 116 mln. 107 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -61 mln. -56,73 mln. | Nettowinst (verlies) 2025 * | -54 mln. -50,22 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 86 mln. 79,98 mln. | Nettoliquiditeiten 2025 * | 68 mln. 63,24 mln. | EV/omzet 2025 * | 2,03 x |
K/w-verhouding 2024 * |
-2,56
x | K/w-verhouding 2025 * |
-2,69
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 79,61% |
Recentste transcriptie over Rezolute, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 66 | 26-07-10 | |
Nevan Elam
CEO | Chief Executive Officer | 56 | 26-07-10 |
Daron Evans
DFI | Director of Finance/CFO | 50 | 24/01 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Nevan Elam
CEO | Chief Executive Officer | 56 | 26-07-10 |
Young-Jin Kim
BRD | Director/Board Member | 67 | 10-02-19 |
Gil Labrucherie
BRD | Director/Board Member | 52 | 20-11-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,04% | 106 mld. | |
+8,09% | 23,47 mld. | |
-14,28% | 21,9 mld. | |
-6,08% | 18,77 mld. | |
-37,26% | 17,85 mld. | |
-8,54% | 16,78 mld. | |
+8,01% | 14,41 mld. | |
+38,60% | 12,86 mld. | |
+318,00% | 8,78 mld. |